Equities research analysts predict that ResMed Inc. (NYSE:RMD) will post $0.84 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for ResMed’s earnings, with the highest EPS estimate coming in at $0.88 and the lowest estimate coming in at $0.80. ResMed reported earnings per share of $0.92 in the same quarter last year, which indicates a negative year over year growth rate of 8.7%. The company is expected to issue its next earnings report on Thursday, April 25th.

On average, analysts expect that ResMed will report full-year earnings of $3.55 per share for the current financial year, with EPS estimates ranging from $3.41 to $3.82. For the next financial year, analysts anticipate that the firm will post earnings of $3.84 per share, with EPS estimates ranging from $3.57 to $4.09. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for ResMed.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, January 24th. The medical equipment provider reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.05. ResMed had a net margin of 18.34% and a return on equity of 26.53%. The firm had revenue of $651.10 million for the quarter, compared to analyst estimates of $676.77 million. During the same period last year, the business earned $1.00 EPS. ResMed’s revenue for the quarter was up 8.3% compared to the same quarter last year.

RMD has been the topic of several research analyst reports. Deutsche Bank lowered shares of ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. JPMorgan Chase & Co. lowered shares of ResMed from a “neutral” rating to an “underweight” rating and set a $99.60 price target on the stock. in a research note on Friday, January 25th. BMO Capital Markets upgraded shares of ResMed from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $109.00 to $127.00 in a research note on Monday, December 10th. Goldman Sachs Group lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Friday, January 25th. Finally, Credit Suisse Group upgraded shares of ResMed from a “neutral” rating to an “outperform” rating in a research note on Friday, October 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $113.20.

Shares of NYSE:RMD opened at $96.81 on Wednesday. ResMed has a 12 month low of $87.67 and a 12 month high of $118.50. The company has a current ratio of 2.44, a quick ratio of 1.76 and a debt-to-equity ratio of 0.61. The firm has a market cap of $13.87 billion, a P/E ratio of 27.42, a P/E/G ratio of 2.57 and a beta of 0.54.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 14th. Shareholders of record on Thursday, February 7th will be paid a $0.37 dividend. The ex-dividend date of this dividend is Wednesday, February 6th. This represents a $1.48 dividend on an annualized basis and a yield of 1.53%. ResMed’s dividend payout ratio is presently 41.93%.

In other ResMed news, CFO Brett Sandercock sold 2,000 shares of ResMed stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $114.18, for a total value of $228,360.00. Following the transaction, the chief financial officer now directly owns 94,390 shares in the company, valued at $10,777,450.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James Hollingshead sold 5,893 shares of ResMed stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $105.52, for a total transaction of $621,829.36. Following the completion of the transaction, the insider now owns 75,121 shares in the company, valued at $7,926,767.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,589 shares of company stock worth $5,964,913. 1.24% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of RMD. Oregon Public Employees Retirement Fund increased its stake in ResMed by 15,868.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,275,028 shares of the medical equipment provider’s stock valued at $46,000 after purchasing an additional 5,241,994 shares during the period. Deutsche Bank AG increased its stake in ResMed by 323.1% in the third quarter. Deutsche Bank AG now owns 1,367,475 shares of the medical equipment provider’s stock valued at $157,721,000 after purchasing an additional 1,044,295 shares during the period. BlackRock Inc. increased its stake in ResMed by 5.2% in the fourth quarter. BlackRock Inc. now owns 11,764,243 shares of the medical equipment provider’s stock valued at $1,339,597,000 after purchasing an additional 583,831 shares during the period. AQR Capital Management LLC increased its stake in ResMed by 151.5% in the third quarter. AQR Capital Management LLC now owns 889,450 shares of the medical equipment provider’s stock valued at $102,590,000 after purchasing an additional 535,803 shares during the period. Finally, Renaissance Technologies LLC increased its stake in ResMed by 149.1% in the third quarter. Renaissance Technologies LLC now owns 747,900 shares of the medical equipment provider’s stock valued at $86,263,000 after purchasing an additional 447,649 shares during the period. Institutional investors own 68.60% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

See Also: Hedge Funds

Get a free copy of the Zacks research report on ResMed (RMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.